ReviewBritish journal of clinical pharmacology2008
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.
Review in British journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 151 citations in OpenAlex.
- A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial.Nature medicine · 2026Trial
- Fasting-mimicking diet counteracts gut microbial dysbiosis in experimental lynch syndrome.Cancer & metabolism · 2026Article
- Review
- Qing-Re-Hua-Shi Decoction ameliorates DSS-induced colitis by modulating multiple signaling pathways and remodeling the gut microbiota and metabolite profile.Frontiers in cellular and infection microbiology · 2025Article
- Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives.Computational and structural biotechnology journal · 2025Review
- Nutraceuticals and biotics in pediatric gastrointestinal disorders.European journal of clinical nutrition · 2024Review
- Priority order of neonatal colonization by a probiotic or pathogenicFrontiers in microbiology · 2024Article
- Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.World journal of gastroenterology · 2023Review
- Therapy Used to Promote Disease Remission Targeting Gut Dysbiosis, in UC Patients with Active Disease.Journal of clinical medicine · 2022Review
- The Probiotic Strains Bifidοbacterium lactis, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Saccharomyces boulardii Regulate Wound Healing and Chemokine Responses in Human Intestinal Subepithelial MyofibroblastsPharmaceuticals (Basel, Switzerland) · 2022Article
- Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease.Advances in nutrition (Bethesda, Md.) · 2022Review
- The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy.Microorganisms · 2022Review
- Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases.International journal of molecular sciences · 2022Review
- Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Review
- Global trends in intestinal flora and ulcerative colitis research during the past 10 years: A bibliometric analysis.Frontiers in microbiology · 2022Article
- Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases.Endocrine, metabolic & immune disorders drug targets · 2022Review
- Association of LRRK2 rs11564258 single nucleotide polymorphisms with type and extent of gastrointestinal mycobiome in ulcerative colitis: a case-control study.Gut pathogens · 2021Article
- Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases.Journal of clinical medicine · 2021Review
- Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPARγ.International journal of molecular sciences · 2021Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intestinal microflora is a large bacterial community that colonizes the gut, with a metabolic activity equal to an organ and various functions that affect the physiology and pathology of the host's mucosal immune system. Intestinal bacteria are useful in promotion of human health, but certain components of microflora, in genetically susceptible individuals, contribute to various pathological disorders, including inflammatory bowel disease. Clinical and experimental observations indicate an imbalance in protective and harmful microflora components in these disorders. Manipulation of gut flora to enhance its protective and beneficial role represents a promising field of new therapeutic strategies of inflammatory bowel disease. In this review, we discuss the implication of gut flora in the intestinal inflammation that justifies the role of probiotics and prebiotics in the prevention and treatment of inflammatory bowel disease and we address the evidence for therapeutic benefits from their use in experimental models of colitis and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.